The US Federal Government is Spending $10 Million to Study the Effects of Medical Marijuana on People

January 2, 2024 ·

In a pioneering effort, Johns Hopkins University is initiating a thorough study to delve into the complexities of medical marijuana usage. As a crucial component of the Cannabis and Health Research Initiative, this expansive research project intends to monitor 10,000 medical marijuana patients for a year.

It systematically gathers data on dosage, consumption methods, product composition, drug interactions, and treatment specifics. The overarching objective is to advance our comprehension of the effectiveness and impact of cannabis therapy across diverse health conditions.

The Need for Quality Data in Cannabis Research

Ryan Vandrey, a key architect of the initiative and a distinguished professor specializing in psychiatry and behavioral sciences at the Johns Hopkins School of Medicine, brought attention to the existing deficit in the quality of data related to cannabis as a therapeutic agent.

In a candid discussion with Hopkins Brain Wise, the university’s newsletter, Vandrey emphasized the unique challenge faced in the realm of cannabis-based treatments. He stated that while they have the availability of cannabis as a therapeutic option, they’re grappling with a deficiency in the quality of data when compared to our understanding of other medicinal substances.

To bridge this informational gap, the research initiative spearheaded by Vandrey and his colleagues is committed to a meticulous approach. Their strategy involves the systematic collection and in-depth analysis of data sourced from a substantial cohort of medical marijuana patients.

This comprehensive methodology is designed not only to fill the existing void in knowledge but also to establish a robust foundation for comprehending the nuanced health impacts associated with therapeutic cannabis use.

The significance of this initiative lies in its potential to revolutionize our understanding of the medical applications of cannabis. By scrutinizing a diverse range of patient experiences, the researchers aim to unearth valuable insights into the effectiveness, safety, and potential risks associated with various cannabis-based therapies.

In doing so, the study aspires to elevate the quality of data in the field, bringing it on par with the standards set by research on more conventional medicines.

Furthermore, the emphasis on meticulous data collection underscores a commitment to scientific rigor. The multidimensional approach of examining dosage, consumption methods, product composition, drug interactions, and treatment details reflects a conscientious effort to leave no stone unturned in pursuing comprehensive knowledge.

This dedication to thoroughness is pivotal in ensuring that the research findings are accurate and applicable across diverse patient populations and medical contexts.

The Cannabis and Health Research Initiative

As part of the broader Cannabis and Health Research Initiative, this study seeks to amalgamate data from its extensive observational research with pre-existing studies. Additionally, the researchers are devising a system to integrate electronic medical records for the identification of medicinal cannabis users, facilitating a comparative analysis with non-users.

Ryan Vandrey underscored the research mission, declaring, “Our objective with this study is to comprehend the health impacts of therapeutic cannabis use.” The primary aim is to provide valuable insights into the efficacy of various products, discern potential risks associated with specific items, and ascertain how different cannabis products may be more or less suitable for particular populations or therapeutic objectives.

Collaboration and Funding

This research endeavor is collaborative, bringing together professionals from diverse fields. Ryan Vandrey is set to collaborate closely with Johannes Thrul, an associate professor specializing in mental health at the Johns Hopkins Bloomberg School of Public Health, alongside other experts involved in the project. Further contributing to this collaborative initiative is the active involvement of the Colorado-based nonprofit organization Realm of Caring.

The financial backing for this pioneering research is substantial, with a $10-million grant from the National Institute on Drug Abuse (NIDA). This considerable financial support serves as a testament to the critical importance placed on advancing our comprehension of cannabis therapy, aiming to unravel its potential benefits and risks in a more nuanced manner.

Methodology and Data Collection

With the aid of the generous grant, researchers plan to collect data from 10,000 volunteers as they progress from the beginning of their cannabis experience through a year or more of medical marijuana use. Johannes Thrul explained the methodology: “We’re tracking them with multiple assessments over the course of their first year, with more tightly spaced assessments toward the beginning.”

The rationale behind this approach is to capture the evolving experiences of individuals as they embark on their medical cannabis journey. As people explore different products to find what best alleviates their symptoms, the researchers aim to gather detailed information on dosage, consumption methods, and product composition.

Significance for Clinical Decision-Making and Research

The extensive registry of data compiled through this study holds significant potential for influencing clinical decision-making and shaping policies and regulatory structures for medical marijuana use. Additionally, the rich dataset could be a valuable resource for developing clinical trials and advancing basic science research related to cannabis therapy.

Ryan Vandrey emphasized the complexity of the cannabis landscape, stating, “Under the umbrella term of cannabis exist hundreds of products that are all different in fundamental and significant ways.” The researchers’ objective is to narrow down the scope, identify areas of real promise, and focus scientific efforts on those specific aspects of cannabis therapy.


Johns Hopkins University’s groundbreaking study of 10,000 medical marijuana patients, part of the Cannabis and Health Research Initiative, is advancing our understanding of cannabis therapy. Led by Professor Ryan Vandrey, the research aims to fill knowledge gaps and establish a robust foundation for comprehending the nuanced health impacts of therapeutic cannabis use. Despite the availability of cannabis as a therapeutic option, the study addresses a deficit in data quality compared to other medicinal substances.

Collaborating with experts like Johannes Thrul and receiving a $10-million grant from the National Institute on Drug Abuse (NIDA) underscores the commitment to advancing cannabis therapy understanding. The study meticulously collects data on dosage, consumption methods, product composition, and treatment specifics, promising insights into the effectiveness, safety, and risks associated with various cannabis-based therapies.

This interdisciplinary initiative aligns with the broader Cannabis and Health Research Initiative, with active involvement from the nonprofit Realm of Caring. As the study progresses, it holds the promise of revolutionizing medical applications of cannabis, contributing to scientific discourse, and guiding informed approaches to therapeutic cannabis use in healthcare. (Full Story)

In categories:Medical Research
Next Post

Wait, Smoking Weed Makes You Skinnier and Have a Lower BMI, Now? - New Study Sheds Light on Why That Is True!

In a recent study featured in the International Journal of Obesity, researchers investigated the impact of cannabis on anthropometric measures. This exploration gains particular significance against the backdrop of the escalating global obesity crisis, affecting approximately 650 million adults, as per the…
Previous Post

Alabama vows 2024 medical marijuana launch despite latest legal obstacle

Alabama regulators ended 2023 with a promise that the first legal sale of medical marijuana will happen sometime in 2024. But MMJ sales in the state cannot begin until dispensary licenses are issued, a process that an Alabama circuit judge temporarily blocked…
Random Post

Would You Take Weed and Magic Mushrooms Together in One Pill? - Doctors Working at CaaMTech on New Medical Breakthrough

Researchers Aim To Combine Psilocybin and Cannabis Into Single Medical Treatment According to a product patent from the renowned marijuana laboratory, CaaMTech, substantial strides have been made in developing a comprehensive treatment that combines cannabinoids and psilocybin for treating both physical and…
Random Post

23 and Counting - Minnesota Becomes the 23rd State to Legalize Recreational Cannabis, Only 27 States Left to Go!

The United States has seen an increase in the legalization of marijuana, and there is rising support for this formerly banned substance nationwide. With the recent passage of a marijuana legalization measure, Minnesota has joined 22 other states. On Memorial Day,…
Random Post

‘Seeds of Change’ report rates states on cannabis equity, finds most lacking

A new report published today—Seeds of Change: Strategies to create an equitable cannabis industry—finds a majority of legal adult-use states lack the laws and policies needed to create a fair and equitable cannabis industry. “Seeds of Change” is a multifaceted…
Random Post

Texas Lawmakers File Three Bills To Expand State-Sponsored Psychedelics Research

Texas lawmakers have filed a series of new bills aimed at promoting and expanding psychedelics research in the state. The Lone Star State took some observers by surprise last session after the conservative legislature enacted a measure to study the therapeutic…